RET FISH analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer.

[1]  Mark Robson,et al.  Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Mansukhani,et al.  Key considerations for comprehensive validation of an RNA fusion NGS panel , 2020, Practical laboratory medicine.

[3]  FDA Approves Selpercatinib; Pralsetinib May Soon Follow. , 2020, Cancer discovery.

[4]  Z. Song,et al.  Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study. , 2020, Clinical lung cancer.

[5]  V. Adamo,et al.  RET fusions in solid tumors. , 2019, Cancer treatment reviews.

[6]  U. Cortes,et al.  Targeted RNA‐sequencing assays: a step forward compared to FISH and IHC techniques? , 2019, Cancer medicine.

[7]  A. Drilon,et al.  PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers , 2019, Journal of Thoracic Oncology.

[8]  Jose Espejo Valle-Inclan,et al.  GRIDSS, PURPLE, LINX: Unscrambling the tumor genome via integrated analysis of structural variation and copy number , 2019, bioRxiv.

[9]  Michael Thomas,et al.  Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). , 2019, Journal of Clinical Oncology.

[10]  Brian C. Haynes,et al.  Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non–Small Cell Lung Cancer , 2019, The Journal of molecular diagnostics : JMD.

[11]  S. Digumarthy,et al.  Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. , 2018, Cancer discovery.

[12]  S. Sleijfer,et al.  Pan-cancer whole-genome analyses of metastatic solid tumours , 2018, bioRxiv.

[13]  A. Shaw,et al.  Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial , 2017, The Lancet. Oncology.

[14]  C. Dooms,et al.  Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Kenneth L. Jones,et al.  Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  L. Bubendorf,et al.  Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens , 2017, European Respiratory Review.

[17]  Ross Camidge,et al.  Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Marchetti,et al.  Testing for ROS1 in non-small cell lung cancer: a review with recommendations , 2016, Virchows Archiv.

[19]  P. Stephens,et al.  Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. , 2015, Lung cancer.

[20]  L. Mazzucchelli,et al.  ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Boram Lee,et al.  Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma , 2015, Modern Pathology.

[22]  R. Herbst,et al.  A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies , 2015, BMC Cancer.

[23]  Jeffrey W. Clark,et al.  Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[24]  Koji Tsuta,et al.  Molecular Mechanisms Underlying Oncogenic RET Fusion in Lung Adenocarcinoma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  Lei Wang,et al.  ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. , 2014, Lung cancer.

[26]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[27]  Shibing Deng,et al.  A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. , 2014, The Journal of molecular diagnostics : JMD.

[28]  T. Kohno,et al.  RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis , 2014, British Journal of Cancer.

[29]  C. Kang,et al.  Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma. , 2013, Lung cancer.

[30]  H. Ji,et al.  RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Dietel,et al.  EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations , 2012, Virchows Archiv.

[32]  H. Sasaki,et al.  RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer , 2012, Cancer medicine.

[33]  F. Carlomagno.  Thyroid Cancer: Role of RET and Beyond , 2012, European Thyroid Journal.

[34]  Seungbok Lee,et al.  A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. , 2012, Genome research.

[35]  G. Turashvili,et al.  Nucleic acid quantity and quality from paraffin blocks: defining optimal fixation, processing and DNA/RNA extraction techniques. , 2012, Experimental and molecular pathology.

[36]  W. Franklin,et al.  Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment , 2010, Clinical Cancer Research.

[37]  J. Cuzick,et al.  Complex patterns of ETS gene alteration arise during cancer development in the human prostate , 2008, Oncogene.

[38]  S A Bustin,et al.  Quantitative real-time RT-PCR--a perspective. , 2005, Journal of molecular endocrinology.

[39]  Sabrina Tosi,et al.  Fluorescence in situ hybridization (FISH), basic principles and methodology. , 2010, Methods in molecular biology.